Axon initiated with a Neutral at UBS

UBS analyst Andrew Spinola initiated coverage of Axon (AXON) with a Neutral rating and $820 price target The company has an “exceptional” growth story but this is fully reflected in the shares at current levels, the analyst tells investors in a research note. The firm says Axon’s share price embeds the company’s strong growth prospects, creating a balanced risk/reward.